BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9675561)

  • 1. Efficacy assessment of highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotropin during pituitary suppression in patients undergoing GIFT for unexplained infertility.
    Campo S; Garcea N
    Gynecol Endocrinol; 1998 Jun; 12(3):161-6. PubMed ID: 9675561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
    Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
    Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pure and highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotrophin for ovarian stimulation after pituitary suppression in in-vitro fertilization.
    Balasch J; Fábregues F; Creus M; Moreno V; Puerto B; Peñarrubia J; Carmona F; Vanrell JA
    Hum Reprod; 1996 Nov; 11(11):2400-4. PubMed ID: 8981119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of using follicle-stimulating hormone preparations depleted of luteinizing hormone to achieve follicular growth in in vitro fertilization.
    Agrawal R; Conway GS; Engmann L; Bekir JS; Jacobs HS
    Gynecol Endocrinol; 1998 Feb; 12(1):9-15. PubMed ID: 9526704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of dehydroepiandrosterone sulfate synthesis in women with polycystic ovary syndrome by human menopausal gonadotropin but not purified urinary follicle stimulating hormone: a comparative pilot study.
    Turkmen S; Backstrom T; Idil M
    Gynecol Endocrinol; 2004 Aug; 19(2):69-78. PubMed ID: 15624268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follicular fluid hormone concentrations after ovarian stimulation using gonadotropin preparations with different FSH/LH ratios. I. Comparison of an FSH-dominant and a purified FSH preparation.
    Duijkers IJ; Willemsen WN; Hollanders HM; Hamilton CJ; Thomas CM; Vemer HM
    Int J Fertil Womens Med; 1997; 42(5):306-10. PubMed ID: 9406836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advantages of recombinant follicle-stimulating hormone over human menopausal gonadotropin for ovarian stimulation in intrauterine insemination: a randomized clinical trial in unexplained infertility.
    Rashidi M; Aaleyasin A; Aghahosseini M; Loloi S; Kokab A; Najmi Z
    Eur J Obstet Gynecol Reprod Biol; 2013 Jul; 169(2):244-7. PubMed ID: 23541417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years: a RCT.
    Moro F; Scarinci E; Palla C; Romani F; Familiari A; Tropea A; Leoncini E; Lanzone A; Apa R
    Hum Reprod; 2015 Jan; 30(1):179-85. PubMed ID: 25398971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful pregnancies in patients with estrogenic anovulation after low-dose human chorionic gonadotropin therapy alone following hMG for controlled ovarian hyperstimulation.
    Lee KL; Couchman GM; Walmer DK
    J Assist Reprod Genet; 2005 Jan; 22(1):37-40. PubMed ID: 15807221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is inversely correlated with a mature oocyte yield and can predict "low responders".
    Ho JY; Guu HF; Yi YC; Chen MJ; Ho ES
    Fertil Steril; 2005 Apr; 83(4):883-8. PubMed ID: 15820795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Could the addition of hp-hMG and GnRH antagonists modulate the response in IVF-ICSI cycles?
    Requena A; Landeras JL; Martínez-Navarro L; Calatayud C; Sánchez F; Maldonado V; Muñoz M; Fernández M; González A; López S; López R; Pacheco A; Calderón G; Martínez V
    Hum Fertil (Camb); 2010 Mar; 13(1):41-9. PubMed ID: 20384441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of highly purified FSH (metrodin-high purity) with pergonal for IVF superovulation.
    Bagratee JS; Lockwood G; López Bernal A; Barlow DH; Ledger WL
    J Assist Reprod Genet; 1998 Feb; 15(2):65-9. PubMed ID: 9513843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of controlled ovarian stimulation with human menopausal gonadotropin or recombinant follicle-stimulating hormone.
    Filicori M; Cognigni GE; Pocognoli P; Tabarelli C; Ferlini F; Perri T; Parmegiani L
    Fertil Steril; 2003 Aug; 80(2):390-7. PubMed ID: 12909504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine profile following stimulation with recombinant follicle stimulating hormone and luteinizing hormone versus highly purified human menopausal gonadotropin.
    Requena A; Cruz M; Ruiz FJ; García-Velasco JA
    Reprod Biol Endocrinol; 2014 Jan; 12():10. PubMed ID: 24476504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
    Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
    Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved oocyte quality is obtained with follicle stimulating hormone alone than with follicle stimulating hormone/human menopausal gonadotrophin combination.
    Mercan R; Mayer JF; Walker D; Jones S; Oehninger S; Toner JP; Muasher SJ
    Hum Reprod; 1997 Sep; 12(9):1886-9. PubMed ID: 9363700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of in vitro fertilization following stimulation with highly purified hMG or recombinant FSH in downregulated women of advanced reproductive age: a prospective, randomized and controlled trial.
    Ye H; Huang G; Pei L; Zeng P; Luo X
    Gynecol Endocrinol; 2012 Jul; 28(7):540-4. PubMed ID: 22390186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of the use of low dose human menopausal gonadotropin in ovulation induction.
    Ku SY; Suh CS; Kim SH; Choi YM; Kim JG; Moon SY
    Eur J Obstet Gynecol Reprod Biol; 2003 Jul; 109(1):55-9. PubMed ID: 12818444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.